Dearborn Partners LLC Maintains Position in Eli Lilly and Company (LLY)
Dearborn Partners LLC maintained its position in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,270 shares of the company’s stock at the close of the 2nd quarter. Dearborn Partners LLC’s holdings in Eli Lilly and were worth $269,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the stock. Ronna Sue Cohen lifted its stake in Eli Lilly and by 0.4% in the 2nd quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after buying an additional 9 shares in the last quarter. Accredited Investors Inc. lifted its stake in Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after buying an additional 14 shares in the last quarter. Sunbelt Securities Inc. lifted its stake in Eli Lilly and by 0.5% in the 1st quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after buying an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC lifted its stake in Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after buying an additional 19 shares in the last quarter. Finally, Oakworth Capital Inc. lifted its stake in Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after buying an additional 20 shares in the last quarter. 75.66% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://theolympiareport.com/2017/10/31/dearborn-partners-llc-maintains-position-in-eli-lilly-and-company-lly.html.
Shares of Eli Lilly and Company (NYSE LLY) opened at 82.65 on Tuesday. The firm has a market capitalization of $87.20 billion, a P/E ratio of 35.76 and a beta of 0.34. The stock’s 50 day moving average price is $84.90 and its 200-day moving average price is $82.19. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.72%. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.88 EPS. On average, equities analysts expect that Eli Lilly and Company will post $4.21 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.52%. Eli Lilly and’s dividend payout ratio is currently 98.58%.
In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 770,000 shares of company stock worth $64,669,850 in the last 90 days. 0.20% of the stock is owned by insiders.
A number of research firms recently issued reports on LLY. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, October 24th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price on the stock in a research note on Thursday, October 26th. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Leerink Swann upped their target price on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and a consensus price target of $89.76.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.